{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:54:14Z","timestamp":1781812454440,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12928-026-01291-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T17:30:10Z","timestamp":1779557410000},"page":"670-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in device selection and clinical outcomes after femoropopliteal endovascular therapy: a multicenter real-world study"],"prefix":"10.1007","volume":"41","author":[{"given":"Shinsuke","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Tobita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Doijiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Hishikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"1291_CR1","doi-asserted-by":"publisher","unstructured":"Nordanstig J, Behrendt CA, Baumgartner I, Belch J, B\u00e4ck M, Fitridge R \u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg, Boyle JR, Brodmann M, Dardik A, Dick F, Go\u00ebffic Y, Holden A, et al. editors. 2024;67:9\u201396. https:\/\/doi.org\/10.1016\/j.ejvs.2023.08.067","DOI":"10.1016\/j.ejvs.2023.08.067"},{"key":"1291_CR2","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","volume":"149","author":"HL Gornik","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149:e1313\u2013410. https:\/\/doi.org\/10.1161\/CIR.0000000000001251.","journal-title":"Circulation"},{"key":"1291_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.5551\/jat.63225","volume":"29","author":"Y Soga","year":"2022","unstructured":"Soga Y, Takahara M, Iida O, Suzuki K, Mori S, Kawasaki D, et al. Ten-year clinical follow-up following bare-nitinol stent implantation for femoropopliteal artery disease. J Atheroscler Thromb. 2022;29:1448\u201357. https:\/\/doi.org\/10.5551\/jat.63225.","journal-title":"J Atheroscler Thromb"},{"key":"1291_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jcin.2015.03.022","volume":"8","author":"O Iida","year":"2015","unstructured":"Iida O, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, et al. 1-year results of the Zephyr registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105\u201312. https:\/\/doi.org\/10.1016\/j.jcin.2015.03.022.","journal-title":"JACC Cardiovasc Interv"},{"key":"1291_CR5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcin.2022.01.019","volume":"15","author":"O Iida","year":"2022","unstructured":"Iida O, Takahara M, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, et al. 1-year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv. 2022;15:630\u20138. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.019.","journal-title":"JACC Cardiovasc Interv"},{"key":"1291_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1526602820960445","volume":"28","author":"O Iida","year":"2021","unstructured":"Iida O, Takahara M, Soga Y, Yamaoka T, Nanto S, Kuratani T, et al. One-year outcomes of heparin-bonded stent-graft therapy for real-world femoropopliteal lesions and the association of patency with the Prothrombotic State based on the prospective, observational, multicenter Viabahn Stent-graft placement for femoropopliteal diseases Requiring Endovascular Therapy (VANQUISH) study. J Endovasc Ther. 2021;28:123\u201331. https:\/\/doi.org\/10.1177\/1526602820960445.","journal-title":"J Endovasc Ther"},{"key":"1291_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jvir.2023.07.023","volume":"34","author":"M Fujihara","year":"2023","unstructured":"Fujihara M, Takahara M, Iida O, Kawasaki D, Soga Y, Tobita K, et al. Endovascular therapy with interwoven nitinol stent placement after Predilation for heavily calcified femoropopliteal artery disease: results of the BURDOCK study. J Vasc Interv Radiol. 2023;34:1929\u201337. https:\/\/doi.org\/10.1016\/j.jvir.2023.07.023.","journal-title":"J Vasc Interv Radiol"},{"key":"1291_CR8","doi-asserted-by":"publisher","first-page":"e025677","DOI":"10.1161\/JAHA.122.025677","volume":"12","author":"Y Soga","year":"2023","unstructured":"Soga Y, Takahara M, Iida O, Tomoi Y, Kawasaki D, Tanaka A, et al. Vessel patency and associated factors of drug-coated balloon for femoropopliteal lesion. J Am Heart Assoc. 2023;12:e025677. https:\/\/doi.org\/10.1161\/JAHA.122.025677.","journal-title":"J Am Heart Assoc"},{"key":"1291_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3348\/kjr.2011.12.2.203","volume":"12","author":"IS Chang","year":"2011","unstructured":"Chang IS, Chee HK, Park SW, Yun IJ, Hwang JJ, Lee SA, et al. The primary patency and fracture rates of self-expandable nitinol stents placed in the popliteal arteries, especially in the P2 and P3 segments, in Korean patients. Korean J Radiol. 2011;12:203\u20139. https:\/\/doi.org\/10.3348\/kjr.2011.12.2.203.","journal-title":"Korean J Radiol"},{"key":"1291_CR10","first-page":"479","volume":"20","author":"S Lewitton","year":"2008","unstructured":"Lewitton S, Babaev A. Superficial femoral artery stent fracture that led to perforation, hematoma and deep venous thrombosis. J Invasive Cardiol. 2008;20:479\u201381.","journal-title":"J Invasive Cardiol"},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"e1107","DOI":"10.4244\/EIJ-D-19-00187","volume":"15","author":"C Bradaric","year":"2019","unstructured":"Bradaric C, Koppara T, M\u00fcller A, Haller B, Ott I, Cassese S, et al. Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. EuroIntervention. 2019;15:e1107\u201314. https:\/\/doi.org\/10.4244\/EIJ-D-19-00187.","journal-title":"EuroIntervention"},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","volume":"373","author":"K Rosenfield","year":"2015","unstructured":"Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1406235.","journal-title":"N Engl J Med"},{"key":"1291_CR13","doi-asserted-by":"publisher","first-page":"e007702","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","volume":"12","author":"JA Laird","year":"2019","unstructured":"Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12:e007702. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.118.007702.","journal-title":"Circ Cardiovasc Interv"},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jvs.2019.05.034","volume":"71","author":"A Mohapatra","year":"2020","unstructured":"Mohapatra A, Saadeddin Z, Bertges DJ, Madigan MC, Al-Khoury GE, Makaroun MS, et al. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. J Vasc Surg. 2020;71:560\u20136. https:\/\/doi.org\/10.1016\/j.jvs.2019.05.034.","journal-title":"J Vasc Surg"},{"key":"1291_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ccd.30622","volume":"101","author":"S Mori","year":"2023","unstructured":"Mori S, Takahara M, Nakama T, Tobita K, Hayakawa N, Iwata Y, et al. Impact of calcification on clinical outcomes after drug-coated balloon angioplasty for superficial femoral artery disease: assessment using the peripheral artery calcification scoring system. Catheter Cardiovasc Interv. 2023;101:892\u20139. https:\/\/doi.org\/10.1002\/ccd.30622.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1291_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3400\/avd.oa.22-00081","volume":"16","author":"K Horie","year":"2023","unstructured":"Horie K, Tanaka A, Taguri M, Tada N. Single-center contemporary clinical outcomes after endovascular treatment in patients with de novo femoropopliteal lesions between 2017 and 2019. Ann Vasc Dis. 2023;16:38\u201345. https:\/\/doi.org\/10.3400\/avd.oa.22-00081.","journal-title":"Ann Vasc Dis"},{"key":"1291_CR17","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1016\/j.jcin.2023.08.022","volume":"16","author":"T Nakama","year":"2023","unstructured":"Nakama T, Takahara M, Iwata Y, Suzuki K, Tobita K, Hayakawa N, et al. Low-dose vs high-dose drug-coated balloon for symptomatic femoropopliteal artery disease: the PROSPECT MONSTER study outcomes. JACC Cardiovasc Interv. 2023;16:2655\u201365. https:\/\/doi.org\/10.1016\/j.jcin.2023.08.022.","journal-title":"JACC Cardiovasc Interv"},{"key":"1291_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2011.09.036","volume":"59","author":"A Tosaka","year":"2012","unstructured":"Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.036.","journal-title":"J Am Coll Cardiol"},{"key":"1291_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.jvs.2023.01.207","volume":"77","author":"S Nagatomi","year":"2023","unstructured":"Nagatomi S, Takahara M, Nakai T, Fujimura N, Yu A, Matsuda D, et al. Comparing the impact of the loss of patency between treatment with drug-coated balloon angioplasty and drug-eluting stent placement. J Vasc Surg. 2023;77:1751\u20139. https:\/\/doi.org\/10.1016\/j.jvs.2023.01.207.","journal-title":"J Vasc Surg"},{"key":"1291_CR20","doi-asserted-by":"publisher","unstructured":"Banerjee S, Sarode K, Mohammad A, Gigliotti O, Baig MS, Tsai S et al. Femoropopliteal artery stent thrombosis: report from the excellence in peripheral artery disease registry. Circ Cardiovasc Interv. 2016;9:e002730. doi: 10.1161\/CIRCINTERVENTIONS.115.002730. Erratum in: Circ Cardiovasc Interv. 2016;9:e000019. https:\/\/doi.org\/10.1161\/HCV.0000000000000019","DOI":"10.1161\/HCV.0000000000000019"},{"key":"1291_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/17085381241258553","volume":"33","author":"H Shimizu","year":"2025","unstructured":"Shimizu H, Kobayashi T, Okazaki T, Mochizuki S, Maeda K, Sato T, et al. Clinical impact of fluoropolymer-based drug-eluting stent thrombosis in femoropopliteal artery occlusive lesions. Vascular. 2025;33:702\u20139. https:\/\/doi.org\/10.1177\/17085381241258553.","journal-title":"Vascular"},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1177\/15266028231223086","volume":"32","author":"Y Tomoi","year":"2025","unstructured":"Tomoi Y, Soga Y, Imada K, Sakai N, Katsuki T, Ando K. Impact of a less than 50% residual stenosis following vessel preparation in femoropopliteal drug-coated balloon angioplasty. J Endovasc Ther. 2025;32:1944\u201352. https:\/\/doi.org\/10.1177\/15266028231223086.","journal-title":"J Endovasc Ther"},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jcin.2022.01.001","volume":"15","author":"RB Allan","year":"2022","unstructured":"Allan RB, Puckridge PJ, Spark JI, Delaney CL. The impact of intravascular ultrasound on femoropopliteal artery endovascular interventions: a randomized controlled trial. JACC Cardiovasc Interv. 2022;15:536\u201346. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.001.","journal-title":"JACC Cardiovasc Interv"},{"key":"1291_CR24","doi-asserted-by":"publisher","unstructured":"Tsukizawa T, Fujihara M, Yazu Y. Application of drug-eluting stent with drug-coated balloon strategy for the endovascular treatment of long-segment femoropopliteal artery disease. J Endovasc Ther. 2024;15266028241292459. https:\/\/doi.org\/10.1177\/15266028241292459.","DOI":"10.1177\/15266028241292459"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-026-01291-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:04:46Z","timestamp":1781809486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-026-01291-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s12928-026-01291-1","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was reviewed and approved by the institutional review boards of the participating institutions. Given the retrospective nature of the study, the requirement for written informed consent was waived. Patients were provided the opportunity to opt out of participation through publicly available information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was waived due to the retrospective design of the study. Patients were provided with the opportunity to opt out in accordance with institutional regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"S.M. has received speaker\u2019s fees from Becton Dickinson (BD), Kaneka Medics, Boston Scientific Japan, Medtronic, and Terumo. K.T. serves as a proctor for Gore, Philips, Merit Medical, and Japan Lifeline; is a consultant for Cordis; and has received honoraria from Medtronic, Kaneka Medics, Medicon, Terumo, Amgen, and Novartis. S.T. has received research grants and honoraria from Boston Scientific Japan, Edwards Lifesciences, Asahi Intecc, Terumo Corporation, Shockwave Medical, and Medtronic. M.T. has received speaker\u2019s fees from Abbott. Y.I. has received speaker\u2019s fees from Abbott, Terumo, Boston Scientific Japan, Medtronic, and NIPRO. The other authors declare no conflicts of interest related to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}